JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: We and others have shown that destabilization of the BCR-ABL/JAK2 network with JAK2 inhibitors and TKIs dissociates their physical interaction and sensitizes CML LSCs to TKIs.